# US 2003/0114396 A1 · 11-O-substituted macrolides and their descladinose derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0114396 A1
- Document ID: US20030114396A1
- Status: Published application
- Kind: A1
- Application number: 10/011,322
- Filed: 2001-12-03
- Published: 2003-06-19
- Earliest claimed: 2001-12-03
- Assignees: Enanta Pharmaceuticals, Inc.
- Inventors: Ly Tam Phan Phan; Deqiang Niu; Yat Sun Or
- Web page: https://patentgrep.com/patent/US20030114396A1

## CPC

- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

There are described 11-O-substituted macrolides and their descladinose derivatives and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described is a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compounds.

## Claims

### Claim 1

A compound represented by formula (I) or a pharmaceutical ester, salt or prodrug thereof:
7
A is selected from the group consisting of:
(1) C1-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of:
i. halogen;
ii. aryl;
iii. substituted aryl;
iv. heteroaryl;
v. substituted heteroaryl;
vi. —O—R5, where R5 is selected from the group consisting of:
a. hydrogen;
b. aryl;
c. substituted aryl;
d. heteroaryl; and
e. substituted heteroaryl; and
vii. —O—C1-C6-alkyl-R5, where R5 is as previously defined;
viii. —O—C2-C6-alkenyl-R5, where R5 is as previously defined;
ix. —O—C2-C6-alkynyl-R5, where R5 is as previously defined; and
x. —NR6R7, where R6 and R7 are each independently selected from hydrogen, C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic or R6R7 taken with the nitrogen atom to which they are connected form a 3- to 7-membered ring which may optionally contain one or more hetero functions selected from the group consisting of —O—, —NH—, —N(C1-C6-alkyl)-, —N(aryl)-, —N(heteroaryl)-, —S—, —S(O)— and —S(O)2—;
(2) —C(O)—R5, where R5 is as previously defined;
(3) —C(O)—C1-C6-alkyl-R5, where R5 is as previously defined;
(4) —C(O)—C2-C6-alkenyl-R5, where R5 is as previously defined;
(5) —C(O)—C2-C6-alkynyl-R5, where R5 is as previously defined;
(6) —C1-C6-alkyl-M-R5, where M=—OC(O)—, —OC(O)O—, —OC(O)NR6—, —NR6C(O)—, —NR6C(O)O—, —NR6C(O)NR7-, —NR6C(N)NR7-, S(O)n—, where n=0, 1 or 2, and where R5, R6, R7 are as previously defined;
(7) —C2-C6-alkenyl-M-R5, where M=—OC(O)—, —OC(O)O—, —OC(O)NR6—, —NR6C(O)—, —NR6C(O)O—, —NR6C(O)NR7-, —NR6C(N)NR7-, S(O)n—, where n=0, 1 or 2, and where R5, R6, R7 are as previously defined; and
(8) —C2-C6-alkynyl-M-R5, where M=—OC(O)—, —OC(O)O—, —OC(O)NR6—, —NR6C(O)—, —NR6C(O)O—, —NR6C(O)NR7-, —NR6C(N)NR7-, S(O)n—, where n=0, 1 or 2, and where R5, R6, R7 are as previously defined;
R1 is selected from the group consisting of:
(1) hydrogen;
(2) R3, where R3 is C1-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of:
a. halogen;
b. aryl;
c. substituted aryl;
d. heteroaryl;
e. substituted heteroaryl;
f. —O—C1-C6-alkyl-R5, where R5 is as previously defined; and
g. —NR6R7, where R6 and R7 are as previously defined;
(3) —C(=O)—R4, where R4 is H or R3, where R3 is as previously defined;
(4) —C(=O)O—R3, where R3 is as previously defined; and
(5) —C(=O)N—R6R7, where R6 and R7 are as previously defined;
Rp1 is hydrogen or hydroxy protecting group; and
Z is selected from the group consisting of:
(1) hydrogen;
(2) hydroxy protecting groups; and
(3) —X—R3, where X=—C(O)—, —C(O)O—, —C(O)NH—, or absent, and R3 is as previously defined.

### Claim 2

A compound represented by formula (II) or a pharmaceutical ester, salt or prodrug thereof:
8
A is selected from the group consisting of:
(1) C1-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of:
i. halogen;
ii. aryl;
iii. substituted aryl;
iv. heteroaryl;
v. substituted heteroaryl;
vi. —O—R5, where R5 is selected from the group consisting of:
a. hydrogen;
b. aryl;
c. substituted aryl;
d. heteroaryl; and
e. substituted heteroaryl;
vii. —O—C1-C6-alkyl-R5, where R5 is as previously defined;
viii. —O—C2-C6-alkenyl-R5, where R5 is as previously defined;
ix. —O—C2-C6-alkynyl-R5, where R5 is as previously defined; and
x. —NR6R7, where R6 and R7 are each independently selected from hydrogen, C1-C6-alkyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic, C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of halogen, aryl, substituted aryl, heterocyclic and substituted heterocyclic or R6R7 taken with the nitrogen atom to which they are connected form a 3- to 7-membered ring which may optionally contain one or more hetero functions selected from the group consisting of —O—, —NH—, —N(C1-C6-alkyl)-, —N(aryl)-, —N(heteroaryl)-, —S—, —S(O)— and —S(O)2—;
(2) —C(O)—R5, where R5 is as previously defined;
(3) —C(O)—C1-C6-alkyl-R5, where R5 is as previously defined;
(4) —C(O)—C2-C6-alkenyl-R5, where R5 is as previously defined;
(5) —C(O)—C2-C6-alkynyl-R5, where R5 is as previously defined;
(6) —C1-C6-alkyl-M-R5, where M=—OC(O)—, —OC(O)O—, —OC(O)NR6—, —NR6C(O)—, —NR6C(O)O—, —NR6C(O)NR7-, —NR6C(N)NR7-, S(O)n—, where n=0, 1 or 2, and where R5, R6, R7 are as previously defined;
(7) —C2-C6-alkenyl-M-R5, where M=—OC(O)—, —OC(O)O—, —OC(O)NR6—, —NR6C(O)—, —NR6C(O)O—, —NR6C(O)NR7-, —NR6C(N)NR7-, S(O)n—, where n=0, 1 or 2, and where R5, R6, R7 are as previously defined; and
(8) —C2-C6-alkynyl-M-R5, where M=—OC(O)—, —OC(O)O—, —OC(O)NR6—, —NR6C(O)—, —NR6C(O)O—, —NR6C(O)NR7-, —NR6C(N)NR7-, S(O)n—, where n=0, 1 or 2, and where R5, R6, R7 are as previously defined;
R1 is selected from the group consisting of:
(1) hydrogen;
(2) R3, where R3 is C1-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl, optionally substituted with one or more substituents selected from the group consisting of:
a. halogen;
b. aryl;
c. substituted aryl;
d. heteroaryl;
e. substituted heteroaryl;
f. —O—C1-C6-alkyl-R5, where R5 is as previously defined; and
g. —NR6R7, where R6 and R7 are as previously defined;
(3) —C(=O)—R4, where R4 is H or R3 as previously defined;
(4) —C(=O)O—R3, where R3 is as previously defined; and
(5) —C(=O)N—R6R7, where R6 and R7 are as previously defined;
R2 is selected from the group consisting of:
(1) hydroxy protecting group;
(2) R5, where R5 is as previously defined;
(3) —X—Y—R5, where R5 is as previously defined, X=—C(O)—, —C(O)O—, —C(O)NH—, or absent, and Y=C1-C6-alkyl, or absent; and
(4) C1-C6-alkyl, C2-C6-alkenyl or C2-C6-alkynyl optionally substituted with one or more substituents selected from the group consisting of:
a. halogen;
b. aryl;
c. substituted aryl;
d. heteroaryl;
e. substituted heteroaryl;
f. —O—R5, where R5 is as previously defined;
g. —O—C1-C6-alkyl-R5, where R5 is as previously defined;
h. —O—C2-C6-alkenyl-R5, where R5 is as previously defined;
i. —O—C2-C6-alkynyl-R5, where R5 is as previously defined; and
j. —NR6R7, where R6 and R7 are as previously defined; and
Rp1 is hydrogen or hydroxy protecting group.

### Claim 3 (depends on 1, 2)

A compound as defined in claims 1 or 2 or a pharmaceutical ester, salt or prodrug thereof which is selected from the group consisting of:
Compound of formula I: A=—CH2CH=CH2, R1=H, RP1=H, Z=acetyl; Compound of formula I: A=—CH2CH=CH-(3-quinolyl), R1=H, RP1=H, Z=acetyl; Compound of formula I: A=—CH2CH2CH2-(3-quinolyl), R1=H, RP1=H, Z=acetyl; Compound of formula I: A=—CH2CH2CH2-(3-quinolyl), R1=H, RP1=H, Z=H; Compound of formula I: A=—CH2CH=CH-(3-quinolyl), R1=H, RP1=H, Z=H; Compound of formula I: A=R1=—CH2CH=CH2, RP1=H, Z=acetyl; Compound of formula I: A=—CH2CH=CHCH2-(4phenyl-1-imidazolyl), R1=H, RP1=H, Z=acetyl; Compound of formula I: A=—CH2CH2CH2CH2-(4-phenyl-1-imidazolyl), R1=H, RP1=H, Z=acetyl; Compound of formula I: A=—CH2CH2CH2CH2-(4-phenyl-1-imidazolyl), R1=H, RP1=H, Z=H; Compound of formula I: A=—CH2CH2CH2CH2-(4-phenyl-1-imidazolyl), R1=—CH2CH=CH2, Rp1=H, Z=acetyl; Compound of formula I: A=—CH2CH=CHCH2CH2-(4-phenyl-1-imidazolyl), R1=Rp1=H, Z=acetyl; Compound of formula I: A=—CH2CH2CH2CH2CH2-(4-phenyl-1-imidazolyl), R1=—CH2CH=CH2, Rp1=H, Z=acetyl; Compound of formula I: A=—CH2CH2CH2CH2-(4-(3-pyridyl)-1-imidazolyl), R1=H, RP1=H, Z=acetyl; Compound of formula I: A=—CH2CH2CH2CH2-(4-(3-pyridyl)-1-imidazolyl), R1=H, RP1=H, Z=H; Compound of formula I: A=—CH2CH2CH2CH2-(4-(3-pyridyl)-1-imidazolyl), R1=H, RP1=H, RP2=—CH2CH=CH2; Compound of formula II: A=—CH2CH=CH2, R1=H, RP1=H, R2=H; Compound of formula II: A=—CH2CHCH2, R1=H, R2=—C(O)CH2-(2-pyridyl), RP1=H; Compound of formula II: A=—CH2CH2CH2-(3-quinolyl), R1=H, R2=H and RP1=H; and Compound of formula II: A=—CH2CH2CH2-(3-quinolyl), R1=H, R2=H, RP1=H.

### Claim 4 (depends on 1, 2, 3)

A pharmaceutical composition for treating bacterial infections comprising a therapeutically effective amount of a compound of claims 1, 2 or 3 or a pharmaceutically acceptable salt, ester or prodrug thereof in combination with a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1, 2, 3)

A method for treating bacterial infections comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a therapeutically-effective amount of a compound of claims 1, 2 or 3 or a pharmaceutically acceptable salt, ester or prodrug thereof.

### Claim 6 (depends on 1)

A process for the preparation of a compound represented by formula I, as in claim 1 comprising the steps:
(a) reacting a compound represented by the formula:
9
where Rp1 and Z are as defined in claim 1, with a tert-butyl allyl carbonate and a palladium catalyst with a phosphorus ligand in an aprotic solvent to provide a compound represented by the formula:
10
(b) reacting the product of step (a) with an aryl halide or an aryl triflate, where the said aryl group is the group R that is selected from an aryl, heteroaryl, substituted aryl, or substituted heteroaryl group, in the presence of a palladium catalyst with a phosphorus ligand to provide a compound represented by the formula:
11
(c) the product of step (b) is optionally first hydrogenated, with palladium on carbon under hydrogen at a temperature between 0° C. to 50° C., or directly treated with methanol from 0° C. to 60° C. to provide a compound represented by the formula:
12
(d) the product of step (c) is then further deprotected by acid hydrolysis, base hydrolysis, tetrabutylammonium fluoride or hydrofluoric acid to provide a compound represented by formula I in claim 1, where A=—CH2CH=CHR or —CH2CH2CH2R, and R1, Rp1 and Z are each H.

### Claim 7 (depends on 1)

A process for the preparation of a compound represented by formula I, as in claim 1 comprising the steps:
(a) reacting a compound represented by the formula:
13
where Rp1 and Z are as defined in claim 1, with an aryl-alkenyl derivative of the formula R—(CH2)n—CH=CH, where n=1, 2 or 3, using ruthenium catalysts, where the said R group is selected from an aryl, heteroaryl, substituted aryl, or substituted heteroaryl group, at a temperature between 0° C. to 50° C. in an aprotic solvent to provide a compound represented by the formula:
14
(b) the product of step (a) is optionally first hydrogenated, with palladium on carbon under hydrogen at a temperature between 0° C. to 50° C., or directly treated with methanol from 0° C. to 60° C. to provide a compound represented by the formula:
15
(c) the product of step (b) is then further deprotected by acid hydrolysis, base hydrolysis, tetrabutylammonium fluoride or hydrofluoric acid to provide a compound represented by Formula I in claim 1, where A=—CH2CH=CH(CH2)nR or —CH2CH2CH2(CH2)nR where n=1, 2 or 3, and R1, Rp1 and Z are each H.

### Claim 8 (depends on 1)

A process for the preparation of a compound represented by formula I, as in claim 1 comprising the steps:
(a) reacting a compound represented by the formula:
16
where A, Rp1 and Z are as defined in claim 1, with a tert-butyl allyl carbonate catalyzed by a palladium catalyst with a phosphorus ligand in an aprotic solvent for 30 to 40 hours at a temperature between room temperature to 100° C. to provide a compound represented by the formula:
17
(b) the product of step (a) is treated with methanol from 0° C. to 60° C. to provide a compound represented by the formula:
18
(c) the product of step (c) is then further deprotected by acid hydrolysis, base hydrolysis, tetrabutylammonium fluoride or hydrofluoric acid to provide a compound represented by formula I in claim 1, where A is as defined in claim 1, R1=—CH2CH=CH, and Rp1 and Z are each H.

### Claim 9 (depends on 2)

A process for the preparation of a compound represented formula II, as in claim 2 comprising the steps:
(a) reacting a compound represented by the formula:
19
where A, R1, Rp1 and Z are as defined in claim 2, with dilute aqueous acid at a temperature between 0° C. to 70° C. to provide a compound represented by the formula:
20
(b) the product of step (a) is treated with either an alkylating agent in the presence of a base at a temperature between −20° C. to 60° C. or an acylating agent optionally with a coupling agent to provide a compound represented by the formula:
21
(c) the product of step (a) is treated with methanol from 0° C. to 60° C. to provide a compound represented by formula II in claim 2, where A, R1 and R2 are as defined in claim 2, and Rp1 is H.
